Newsletter Tool

Today’s Big News

Aug 14, 2024

Metagenomi axes ALS program after seeing Biogen and Ionis flounder

Evotec eyes 400 layoffs, citing 'challenging market'

Gone are the days of Galera: Biotech says goodbye to staffers and initiates wind down

Acelyrin loses interest in izokibep, lays off 3rd of staff to focus on looming fight for Tepezza's crown

Kezar drops solid tumor drug that has yet to prove worth in phase 1

Viracta lays off 23% of staff, pauses program to slim down for race to finish line in lymphoma

Scientists discover free-floating bacterial gene that challenges cardinal rules of biology

Featured

Metagenomi axes ALS program after seeing Biogen and Ionis flounder

By Nick Paul Taylor

Metagenomi is editing its pipeline, choosing to seek a partner for a program Moderna dropped and axing its amyotrophic lateral sclerosis activities in response to setbacks at a competitor.

Evotec eyes 400 layoffs, citing 'challenging market'

By James Waldron

Evotec has set its sights on scrapping about 400 roles as the German company continues to battle tough market conditions.

Gone are the days of Galera: Biotech says goodbye to staffers and initiates wind-down

By Gabrielle Masson

Galera Therapeutics is shuttering, with the biotech’s board OK'ing a liquidation plan that whittles down the company’s workforce to just three people.

Acelyrin loses interest in izokibep, lays off 3rd of staff to focus on looming fight for Tepezza's crown

By Darren Incorvaia

Despite maintaining its recent winning streak in the clinic, Acelyrin is no longer focused on its former lead asset izokibep.

Kezar drops solid tumor drug that has yet to prove worth in phase 1

By James Waldron

Kezar Life Sciences is dropping its unpromising phase 1 solid tumor drug as the biotech goes all-in on its lead autoimmune hepatitis program.

Viracta lays off 23% of staff, pauses program to slim down for race to finish line in lymphoma

By Nick Paul Taylor

Viracta Therapeutics is going all-in on its lymphoma program. The biotech responded to phase 2 data by throwing its resources behind a plan to file for a blood cancer approval in 2026, hitting pause on its solid tumor program and putting 23% of its staff out of a job in the process.

Scientists discover free-floating bacterial gene that challenges cardinal rules of biology

By Darren Incorvaia

Neo is a free-floating, ephemeral gene that is made by bacteria only when they are infected by a virus—it doesn't exist anywhere in the genome.

J&J and Roche are the strongest companies in the biopharma industry, says S&P Global

By Kevin Dunleavy

Johnson & Johnson and Roche are at the top of S&P Global’s pharmaceutical industry power ratings, which assess the strength of the world’s top 17 drugmakers.

White House announces $150M in ARPA-H awards for precision cancer surgery

By Conor Hale

The Biden administration will deliver $150 million in cancer moonshot funds to new tech that aims to make tumor surgeries safer and more precise.

Biotech leader jumps to oncology CRO Pi Health

By Darren Incorvaia

Oncology-focused CRO Pi Health has added a new chef to its executive kitchen by appointing Alex Morozov, M.D., Ph.D., as its first chief medical officer.

Moderna unveils free Coursera curriculum on mRNA medicines to boost STEM skills

By Andrea Park

With analysts estimating that millions of jobs in the STEM fields are currently going unfilled in the U.S., Moderna is doing its part to strengthen the workforce and close that gap.

Fierce podcasts

Don’t miss an episode

A closer look at Fierce Biotech's Fierce 15

In this week's episode of "The Top Line," we’re diving into Fierce Biotech’s annual Fierce 15 special report.

What the data says about the telehealth market

Fierce 15: Where are they now?

Resources

Whitepaper

Launching a Product in Europe: Understanding Supply Chain Cost Drivers

This paper explores the costs of setting up a supply chain in Europe for a new biopharma therapy. It outlines key cost drivers & the various levers decision makers can use to affect those costs.

Efficient-Pro Medium and Feed 1 enable rapid and seamless upstream process development and scale-up for CHO-K1 cells

Download the white paper to learn how this innovative solution can help optimize your mAb production processes. The findings demonstrate the system's robust capability to sustain strong cell growth and high productivity, facilitating a smooth transition from laboratory to production scale.

2024 Life Sciences Industry Outlook

The definitive report on the state of our industry. Readers will gain an understanding of key indicators to monitor, future predictions, and guidance for investors and founders navigating the therapeutic enabling tools and services, healthtech and techbio sectors through 2024 and beyond.